Literature DB >> 27889021

Neuroimaging of Peptide-based Vaccine Therapy in Pediatric Brain Tumors: Initial Experience.

Andre D Furtado1, Rafael Ceschin2, Stefan Blüml3, Gary Mason4, Regina I Jakacki4, Hideho Okada5, Ian F Pollack6, Ashok Panigrahy7.   

Abstract

The potential benefits of peptide-based immunotherapy for pediatric brain tumors are under investigation. Treatment-related heterogeneity has resulted in radiographic challenges, including pseudoprogression. Conventional MR imaging has limitations in assessment of different forms of treatment-related heterogeneity, particularly regarding distinguishing true tumor progression from efficacious treatment responses. Advanced neuroimaging techniques, including diffusion magnetic resonance (MR), perfusion MR, and MR spectroscopy, may add value in the assessment of treatment-related heterogeneity. Observations suggest that recent delineation of specific response criteria for immunotherapy of adult brain tumors is likely relevant to the pediatric population and further validation in multicenter pediatric brain tumor peptide-based vaccine studies is warranted. Copyright Â
© 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  MR spectroscopy; Pediatric brain tumors; Pseudoprogression; Vaccine therapy

Mesh:

Substances:

Year:  2017        PMID: 27889021      PMCID: PMC5127439          DOI: 10.1016/j.nic.2016.09.002

Source DB:  PubMed          Journal:  Neuroimaging Clin N Am        ISSN: 1052-5149            Impact factor:   2.264


  62 in total

1.  Ex vivo MR spectroscopic measure differentiates tumor from treatment effects in GBM.

Authors:  Radhika Srinivasan; Joanna J Phillips; Scott R Vandenberg; Mei-Yin C Polley; Gabriela Bourne; Alvin Au; Andrea Pirzkall; Soonmee Cha; Susan M Chang; Sarah J Nelson
Journal:  Neuro Oncol       Date:  2010-07-20       Impact factor: 12.300

Review 2.  Perfusion MRI using dynamic-susceptibility contrast MRI: quantification issues in patient studies.

Authors:  Fernando Calamante
Journal:  Top Magn Reson Imaging       Date:  2010-04

3.  Proton and sodium MRI assessment of emerging tumor chemotherapeutic resistance.

Authors:  Victor D Schepkin; Kuei C Lee; Kyle Kuszpit; Mukilan Muthuswami; Timothy D Johnson; Thomas L Chenevert; Alnawaz Rehemtulla; Brian D Ross
Journal:  NMR Biomed       Date:  2006-12       Impact factor: 4.044

Review 4.  Proliferation markers for the differential diagnosis of tumor and inflammation.

Authors:  Aren van Waarde; Philip H Elsinga
Journal:  Curr Pharm Des       Date:  2008       Impact factor: 3.116

5.  Glioma proliferation as assessed by 3'-fluoro-3'-deoxy-L-thymidine positron emission tomography in patients with newly diagnosed high-grade glioma.

Authors:  Roland Ullrich; Heiko Backes; Hongfeng Li; Lutz Kracht; Hrvoje Miletic; Kristina Kesper; Bernd Neumaier; Wolf-Dieter Heiss; Klaus Wienhard; Andreas H Jacobs
Journal:  Clin Cancer Res       Date:  2008-04-01       Impact factor: 12.531

6.  Comparison of 18F-fluorodeoxyglucose and 18F-fluorothymidine PET in differentiating radiation necrosis from recurrent glioma.

Authors:  Michael S Enslow; Lauren V Zollinger; Kathryn A Morton; Regan I Butterfield; Dan J Kadrmas; Paul E Christian; Kenneth M Boucher; Marta E Heilbrun; Randy L Jensen; John M Hoffman
Journal:  Clin Nucl Med       Date:  2012-09       Impact factor: 7.794

7.  Low-grade glioma: correlation of short echo time 1H-MR spectroscopy with 23Na MR imaging.

Authors:  R Bartha; J F Megyesi; C J Watling
Journal:  AJNR Am J Neuroradiol       Date:  2008-01-31       Impact factor: 3.825

Review 8.  Neuroimaging of pediatric brain tumors: from basic to advanced magnetic resonance imaging (MRI).

Authors:  Ashok Panigrahy; Stefan Blüml
Journal:  J Child Neurol       Date:  2009-11       Impact factor: 1.987

9.  Myo-inositol: a marker of reactive astrogliosis in glial tumors?

Authors:  Elke Hattingen; Peter Raab; Kea Franz; Friedhelm E Zanella; Heinrich Lanfermann; Ulrich Pilatus
Journal:  NMR Biomed       Date:  2008-03       Impact factor: 4.044

10.  NCI-sponsored trial for the evaluation of safety and preliminary efficacy of 3'-deoxy-3'-[18F]fluorothymidine (FLT) as a marker of proliferation in patients with recurrent gliomas: preliminary efficacy studies.

Authors:  Alexander M Spence; Mark Muzi; Jeanne M Link; Finbarr O'Sullivan; Janet F Eary; John M Hoffman; Lalitha K Shankar; Kenneth A Krohn
Journal:  Mol Imaging Biol       Date:  2009-03-27       Impact factor: 3.488

View more
  4 in total

Review 1.  Current and Future Imaging Methods for Evaluating Response to Immunotherapy in Neuro-Oncology.

Authors:  Benjamin B Kasten; Neha Udayakumar; Jianmei W Leavenworth; Anna M Wu; Suzanne E Lapi; Jonathan E McConathy; Anna G Sorace; Asim K Bag; James M Markert; Jason M Warram
Journal:  Theranostics       Date:  2019-07-09       Impact factor: 11.556

Review 2.  Current Clinical and Pre-Clinical Imaging Approaches to Study the Cancer-Associated Immune System.

Authors:  Christopher G Mueller; Christian Gaiddon; Aïna Venkatasamy
Journal:  Front Immunol       Date:  2021-09-03       Impact factor: 7.561

3.  Considerations when treating high-grade pediatric glioma patients with immunotherapy.

Authors:  Erin Crotty; Kira Downey; Lauren Ferrerosa; Catherine Flores; Bindu Hegde; Scott Raskin; Eugene Hwang; Nicholas Vitanza; Hideho Okada
Journal:  Expert Rev Neurother       Date:  2020-12-17       Impact factor: 4.618

Review 4.  Glioblastoma update: molecular biology, diagnosis, treatment, response assessment, and translational clinical trials.

Authors:  Frank Lieberman
Journal:  F1000Res       Date:  2017-10-26
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.